Adagio Medical Terminates Material Agreement
Ticker: ADGM · Form: 8-K · Filed: Feb 5, 2025 · CIK: 2006986
| Field | Detail |
|---|---|
| Company | Adagio Medical Holdings, INC. (ADGM) |
| Form Type | 8-K |
| Filed Date | Feb 5, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: agreement-termination, material-event
TL;DR
Adagio Medical terminated a key deal on Jan 30th. Details TBD.
AI Summary
Adagio Medical Holdings, Inc. filed an 8-K on February 5, 2025, to report the termination of a material definitive agreement. The agreement was terminated as of January 30, 2025. No specific details about the agreement or the counterparty were provided in this filing.
Why It Matters
The termination of a material definitive agreement can significantly impact a company's operations, financial standing, and future strategic direction.
Risk Assessment
Risk Level: medium — Termination of a material definitive agreement often signals significant business changes or challenges that could affect the company's performance.
Key Players & Entities
- Adagio Medical Holdings, Inc. (company) — Registrant
- January 30, 2025 (date) — Date of termination of agreement
- February 5, 2025 (date) — Filing date of the 8-K
FAQ
What was the nature of the material definitive agreement that was terminated?
The filing does not specify the nature of the material definitive agreement that was terminated.
Who was the counterparty to the terminated agreement?
The filing does not disclose the identity of the other party to the terminated agreement.
What are the specific reasons for the termination of the agreement?
The filing does not provide the reasons for the termination of the material definitive agreement.
What is the potential financial impact of this termination on Adagio Medical Holdings, Inc.?
The filing does not detail the potential financial impact of the agreement's termination.
When was the termination effective?
The termination was effective as of January 30, 2025.
Filing Stats: 587 words · 2 min read · ~2 pages · Grade level 12.4 · Accepted 2025-02-05 14:24:40
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share ADGM The Nasdaq Stock Marke
Filing Documents
- tm255601d1_8k.htm (8-K) — 25KB
- 0001104659-25-009533.txt ( ) — 196KB
- adgm-20250130.xsd (EX-101.SCH) — 3KB
- adgm-20250130_lab.xml (EX-101.LAB) — 33KB
- adgm-20250130_pre.xml (EX-101.PRE) — 22KB
- tm255601d1_8k_htm.xml (XML) — 4KB
02 Termination of a Material Definitive Agreement
Item 1.02 Termination of a Material Definitive Agreement On January 30, 2025, Adagio Medical Holdings, Inc. (the " Company ") provided formal notice to Fjord Ventures LLC (" Fjord ") of its intent to terminate the Facilities and Services Agreement, dated as of June 1, 2011, as amended, by and between Adagio Medical Inc. and Fjord (the " Agreement "), filed as Exhibit 10.27 to the Company's Form S-4 filed with the Securities and Exchange Commission (the " SEC ") on April 19, 2024 , which is incorporated by reference herein. The notice of termination was provided in accordance with the termination provisions outlined in the Agreement. The Agreement will terminate effective July 30, 2025 (the " Termination Date "), which is 180 days from January 31, 2025. The termination is due to the Company no longer needing the services provided under the Agreement. The Agreement provided for various services and facilities to be rendered by Fjord to the Company. These services included employee benefits plan administration, administrative support, IT services, and the provision of office space and supplies. In addition to the Agreement, the Company also sub-leases approximately 4,992 square feet of office and manufacturing space in Laguna Hills, California from Fjord. On March 31, 2024, the sub-lease with Fjord expired. The Company has expressed its willingness to negotiate a new agreement with Fjord in the future for any ongoing services or facility space needs beyond the Termination Date. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: February 5, 2025 Adagio Medical Holdings, Inc. By: /s/ John Dahldorf Name: John Dahldorf Title: Chief Financial Officer